CANbridge Pharmaceuticals begins CAN103 phase 1/2 trial in Gaucher disease
CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease ... Read More
Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease
US gene therapy company Avrobio has secured orphan-drug designation for AVR-RD-02, its investigational gene therapy, for the treatment of Gaucher disease, from the US Food ... Read More